AR090470A1 - Vacuna contra el virus sincicial respiratorio (rsv) - Google Patents

Vacuna contra el virus sincicial respiratorio (rsv)

Info

Publication number
AR090470A1
AR090470A1 ARP130100941A ARP130100941A AR090470A1 AR 090470 A1 AR090470 A1 AR 090470A1 AR P130100941 A ARP130100941 A AR P130100941A AR P130100941 A ARP130100941 A AR P130100941A AR 090470 A1 AR090470 A1 AR 090470A1
Authority
AR
Argentina
Prior art keywords
adenovirus
rsv
region
vaccine against
against respiratory
Prior art date
Application number
ARP130100941A
Other languages
English (en)
Inventor
Radosvic Katarina
H H V Custers Jerme
Vellinga Jort
N Widjojoatmodjo Myra
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of AR090470A1 publication Critical patent/AR090470A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Reivindicación 1: Una vacuna contra virus sincitial respiratorio (VSR), que comprende un adenovirus humano recombinante de serotipo 35 que comprende ácido nucleico que codifica para una proteína F de VSR o un fragmento de la misma. Reivindicación 5: Una vacuna de acuerdo a cualquiera de las reivindicaciones precedentes, en donde el adenovirus humano recombinante tiene una eliminación en la región E1, una eliminación en la región E3, o una eliminación tanto en la región E1 como en la región E3 del genoma adenoviral. Reivindicación 15: Un método para hacer una vacuna contra virus sincitial respiratorio (VSR), que comprende proveer un adenovirus humano recombinante de serotipo 35 que comprende ácido nucleico que codifica para una proteína F de VSR o un fragmento de la misma, propagar dicho adenovirus recombinante en un cultivo de células huéspedes, aislar y purificar el adenovirus recombinante, y formular el adenovirus recombinante en una composición farmacéuticamente aceptable.
ARP130100941A 2012-03-22 2013-03-22 Vacuna contra el virus sincicial respiratorio (rsv) AR090470A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12160682 2012-03-22

Publications (1)

Publication Number Publication Date
AR090470A1 true AR090470A1 (es) 2014-11-12

Family

ID=49221877

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP130100940A AR090469A1 (es) 2012-03-22 2013-03-22 Vacuna contra el virus sincicial respiratorio (rsv)
ARP130100941A AR090470A1 (es) 2012-03-22 2013-03-22 Vacuna contra el virus sincicial respiratorio (rsv)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP130100940A AR090469A1 (es) 2012-03-22 2013-03-22 Vacuna contra el virus sincicial respiratorio (rsv)

Country Status (15)

Country Link
EP (2) EP2827895B1 (es)
JP (2) JP5845376B2 (es)
KR (2) KR102050616B1 (es)
CN (2) CN105431169B (es)
AP (2) AP2014007994A0 (es)
AR (2) AR090469A1 (es)
AU (2) AU2013237424B2 (es)
BR (1) BR112014023196B1 (es)
CA (2) CA2867950C (es)
EA (2) EA026620B1 (es)
MY (2) MY169352A (es)
NZ (2) NZ630753A (es)
SG (2) SG11201405804YA (es)
TW (2) TWI640534B (es)
WO (2) WO2013139911A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211756T1 (hr) 2012-07-05 2022-02-18 Glaxosmithkline Biologicals Sa Novi senzibilizacijsko-pojačivački režimi koji uključuju imunogene polipeptide koje kodiraju polinukleotidi
JP2016516755A (ja) * 2013-04-08 2016-06-09 メディミューン，エルエルシー ワクチン組成物及びその使用方法
MX361774B (es) 2013-04-25 2018-12-17 Janssen Vaccines & Prevention Bv Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados.
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
JP6664338B2 (ja) * 2014-06-13 2020-03-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組合せ物
WO2015195961A1 (en) * 2014-06-18 2015-12-23 Georgia State University And Research Foundation, Inc. Recombinant rsv reporter virus
WO2016144675A1 (en) * 2015-03-06 2016-09-15 Medimmune, Llc Vaccine dose and use thereof
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CA2988654A1 (en) 2015-06-12 2016-12-15 Glaxosmithkline Biologicals S.A. Adenovirus polynucleotides and polypeptides
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
PE20181354A1 (es) 2015-12-23 2018-08-22 Pfizer Mutantes de proteina f de rsv
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
BR112018070323A2 (pt) * 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv vacina contra rsv
RU2758238C2 (ru) 2016-05-12 2021-10-26 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
KR102111244B1 (ko) 2017-02-09 2020-05-15 얀센 백신스 앤드 프리벤션 비.브이. 이종 유전자의 발현을 위한 강력한 짧은 프로모터
WO2018210871A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3624844A1 (en) * 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3681533A1 (en) * 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
US20220273787A1 (en) * 2019-05-15 2022-09-01 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CA3140234A1 (en) * 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
AU2021270777A1 (en) 2020-05-12 2022-11-10 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
RU2731356C9 (ru) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
RU2731342C9 (ru) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
CA3152658A1 (en) * 2020-08-22 2021-04-22 Federal State Budgetary Institution "National Research Centre For Epidemiology And Microbiology Named After The Honorary Academician N.F. Gamaleya" Of The Ministry Of Health Of The Russian Federation Expression vector against severe acute respiratory syndrome virus sars-cov-2
BR112022003611A2 (pt) * 2020-08-22 2022-07-26 Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte Agente farmacêutico para induzir imunidade específica contra sars-cov-2
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗
WO2022215436A1 (ja) * 2021-04-05 2022-10-13 株式会社クボタ 管理機制御システム
CN117018175A (zh) * 2022-05-10 2023-11-10 康希诺生物股份公司 一种呼吸道合胞病毒腺病毒载体疫苗及其制备方法和应用
CN116003536A (zh) * 2022-09-23 2023-04-25 暨南大学 呼吸道合胞病毒融合前f蛋白突变体及其应用
CN117986382A (zh) * 2022-11-04 2024-05-07 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
DE69535178T2 (de) 1994-06-10 2006-12-14 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
KR100503701B1 (ko) 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
BR9908015A (pt) 1998-02-17 2001-04-24 Schering Corp Composições que compreendem vìrus e métodos para concentração de preparações de vìrus
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
EP1133316B1 (en) 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1816205B1 (en) 1999-05-17 2011-08-10 Crucell Holland B.V. Recombinant Adenovirus based on serotype 48 (Ad48).
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
AU4346101A (en) 2000-03-07 2001-09-17 Merck & Co., Inc. Adenovirus formulations
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
US20030232018A1 (en) 2002-01-18 2003-12-18 Berlex Biosciences Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
ES2310247T3 (es) 2002-04-25 2009-01-01 Crucell Holland B.V. Vectores adenovirales estables y metodos de propagacion de los mismos.
SI1497438T1 (sl) 2002-04-25 2010-03-31 Crucell Holland Bv Sredstva in postopki za pripravo adenovirusnih vektorjev
ES2357366T3 (es) 2002-05-14 2011-04-25 MERCK SHARP & DOHME CORP. Procedimientos de purificación de adenovirus.
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
AU2003268210A1 (en) 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CN1863918B (zh) * 2003-10-02 2011-03-30 克鲁塞尔荷兰公司 用于重组腺病毒的包装细胞
AU2005214090B2 (en) 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
ATE491799T1 (de) * 2004-05-26 2011-01-15 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
DE602005025512D1 (de) * 2004-10-13 2011-02-03 Crucell Holland Bv Verbesserte adenovirusvektoren und deren verwendung
AU2006212885A1 (en) * 2005-02-11 2006-08-17 Merck & Co., Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
CN101155915B (zh) 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 利用超滤进行病毒纯化
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
DE102006060799A1 (de) 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
CN101012463A (zh) * 2007-01-19 2007-08-08 安徽医科大学 HDAd/F载体及制备方法和用途
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
ES2532015T3 (es) 2008-11-03 2015-03-23 Crucell Holland B.V. Método para la producción de vectores adenovíricos
US9095546B2 (en) 2009-07-20 2015-08-04 National Health Research Institutes Human respiratory syncytial virus (RSV) vaccine
CN102575233B (zh) 2009-10-15 2014-07-16 克鲁塞尔荷兰公司 从高细胞密度培养物纯化腺病毒的方法
AU2010305765B2 (en) 2009-10-15 2015-07-02 Crucell Holland B.V. Method for the purification of adenovirus particles
WO2011056899A2 (en) * 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
WO2011098592A1 (en) 2010-02-15 2011-08-18 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine

Also Published As

Publication number Publication date
JP5845376B2 (ja) 2016-01-20
KR20140138769A (ko) 2014-12-04
AU2013237424B2 (en) 2017-07-06
BR112014023196A2 (es) 2017-06-20
AU2013237424A1 (en) 2014-10-16
EP2827894A1 (en) 2015-01-28
NZ630649A (en) 2016-12-23
CN105431169A (zh) 2016-03-23
EP2827895B1 (en) 2017-08-09
AR090469A1 (es) 2014-11-12
KR20140138765A (ko) 2014-12-04
TWI640534B (zh) 2018-11-11
BR112014023196B1 (pt) 2021-09-08
CA2867950A1 (en) 2013-09-26
EA201491752A1 (ru) 2015-02-27
EP2827895A1 (en) 2015-01-28
CA2867955A1 (en) 2013-09-26
JP5805908B2 (ja) 2015-11-10
CA2867950C (en) 2023-02-21
KR102023791B1 (ko) 2019-09-23
EP2827894B1 (en) 2017-05-17
WO2013139911A1 (en) 2013-09-26
SG11201405804YA (en) 2014-10-30
EA026504B1 (ru) 2017-04-28
JP2015512380A (ja) 2015-04-27
AU2013237429A1 (en) 2014-10-09
CN105431169B (zh) 2019-04-02
AU2013237429B2 (en) 2015-07-23
JP2015519295A (ja) 2015-07-09
MY169352A (en) 2019-03-25
AP2014007993A0 (en) 2014-10-31
CN104334188B (zh) 2016-08-24
TW201343669A (zh) 2013-11-01
AP2014007994A0 (en) 2014-10-31
TW201341531A (zh) 2013-10-16
CN104334188A (zh) 2015-02-04
MY169331A (en) 2019-03-21
TWI624545B (zh) 2018-05-21
NZ630753A (en) 2016-12-23
CA2867955C (en) 2023-02-07
WO2013139916A1 (en) 2013-09-26
KR102050616B1 (ko) 2019-12-03
EA201491754A1 (ru) 2014-12-30
EA026620B1 (ru) 2017-04-28
SG11201405803PA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
CO2018005215A2 (es) Construcciones específicas del hígado para expresión del factor viii
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
TN2018000155A1 (en) Herpes simplex virus vaccine
EP4349404A3 (en) Respiratory virus vaccines
AR096113A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
EA201792663A1 (ru) Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
BR112019024813A2 (pt) adenovírus recombinantes portando transgenes
BR112017007737A2 (pt) variantes de aav recombinantes e usos das mesmas
BR112018007538A2 (pt) células exterminadoras naturais e células ilc3 e usos das mesmas
BR112015022790A2 (pt) molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral
SG194751A1 (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
BR112015008930A2 (pt) vacinas baseadas em partícula recombinante contra a infecção por citomegalovírus humano
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
EA201390806A1 (ru) Конструкция пептидного каркаса
WO2013158664A3 (en) Use of p16 promoter for selective killing of senescent cells
WO2014060848A3 (en) Treatment methods using adenovirus
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
AR101597A1 (es) Proteínas de fusión uti (inhibidor de tripsina urinaria)
BR112016000874A2 (pt) vírus de rna oncolítico geneticamente estável, método de fabricação e uso dos mesmos
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
EA201592298A1 (ru) Полуживая вирусная вакцина против респираторно-синцитиального вируса
BR112015004965A2 (pt) silenciamento de gene transcricional de endogenes em plantas

Legal Events

Date Code Title Description
FB Suspension of granting procedure